{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gord-in-children/prescribing-information/omeprazole/","result":{"pageContext":{"chapter":{"id":"81949c9c-d9f4-5246-ba10-93e03d3d5c2b","slug":"omeprazole","fullItemName":"Omeprazole","depth":2,"htmlHeader":"<!-- begin field da56dc39-8f61-4dc1-be12-ef1088be8193 --><h2>Omeprazole</h2><!-- end field da56dc39-8f61-4dc1-be12-ef1088be8193 -->","summary":"","htmlStringContent":"<!-- begin item 8bc38136-21c6-4f16-9ec1-b2ff336d8721 --><!-- end item 8bc38136-21c6-4f16-9ec1-b2ff336d8721 -->","topic":{"id":"3450f996-245b-5f1c-9e7b-4ac79aed190b","topicId":"82055e52-e2bf-4f1f-b8dd-b6cfff4b5cba","topicName":"GORD in children","slug":"gord-in-children","lastRevised":"Last revised in September 2020","chapters":[{"id":"6dd62a16-ccde-575f-9138-028d0f7249d5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5c4344fa-cc04-5c8a-8525-0117f05a2a3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95a987c9-7f19-57c2-82eb-6673330f1a33","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5a628000-fddd-591e-aa4a-f3a5d27a3b54","slug":"changes","fullItemName":"Changes"},{"id":"76aa1188-2e33-55c6-ba4c-d13b6c09db53","slug":"update","fullItemName":"Update"}]},{"id":"939fae21-c502-5912-ad61-afb229a9fac5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"23c2943f-6ecf-5571-a559-9818348552ba","slug":"goals","fullItemName":"Goals"},{"id":"caee2b08-a4c2-5fa3-8d43-130a043b68d9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5fb28217-0443-5bfa-a971-4909a5a6c93b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"72771ba0-2707-5c43-b059-6d539cc568df","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"33debdff-0f33-531f-b7c3-a3123aa752ac","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5b53e0cd-2b10-5e6f-99ad-e832ae9dde2e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0534b6c6-d8fb-5482-910c-3890eccd28a1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b0622c3b-0b7d-5e06-ac6e-b48f44307885","slug":"definition","fullItemName":"Definition"},{"id":"6dc898dd-dd38-5627-be60-ce0f218fcc6f","slug":"causes","fullItemName":"Causes"},{"id":"71b6272e-eb35-5e68-8449-c464d77d7563","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"844a2a73-bae8-5ae2-a218-4de702392498","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7924f80b-3369-54d7-a800-9a0bb22a0242","slug":"complications","fullItemName":"Complications"},{"id":"6ef64f28-7f65-5aaa-8e40-c5ed7f3ead77","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1bff5828-94a1-5984-8ed1-8cde69104288","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fd58f48a-9a7b-50dd-9c0e-d1c4826f6326","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"4ab712ac-c731-5386-8b93-5afa98f37717","slug":"assessment","fullItemName":"Assessment"},{"id":"5e9aff96-e1cf-58e7-9de4-ffdfa742df08","slug":"differential-diagnosis-red-flag-features","fullItemName":"Differential diagnosis/'red flag' features"}]},{"id":"9ac089f7-44bb-5da5-87a5-a065775dcea0","fullItemName":"Management","slug":"management","subChapters":[{"id":"cfa333ea-866c-555f-8a74-08b659ba92cb","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"3c2116b9-ca53-5715-b7ed-02d6e146d463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"775cc2f7-5cf2-5e72-9ffe-a06fbbe7bc17","slug":"gavisconr-infant","fullItemName":"Gaviscon® Infant"},{"id":"0f6b46fc-04ae-528e-8a4f-182488436dd7","slug":"ranitidine","fullItemName":"Ranitidine"},{"id":"81949c9c-d9f4-5246-ba10-93e03d3d5c2b","slug":"omeprazole","fullItemName":"Omeprazole"}]},{"id":"033a9c06-1742-5548-9885-53d54c7cc3b0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"558cd112-f11b-5b2e-a9a9-80f699b1dee5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9f5b615b-0570-5ba7-8d7a-d4cc5a4dd033","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"30b65237-637c-50a8-90fe-3c945c1a3ee1","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"45d4b60b-a070-544b-9f14-bee3b54e7f3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"58c86f1d-bcc1-59b5-90c0-4a4c75374532","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0691004e-29d1-5b9f-b06e-90eeba4ce3f5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7490205e-5357-534e-bf5f-2f2aad729683","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3c2116b9-ca53-5715-b7ed-02d6e146d463","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"bee84a68-b75c-5f83-998c-499ca8ecef73","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 6bacd679-47e1-45ba-b7c4-911afed87fe4 --><h3>What is the recommended dose?</h3><!-- end field 6bacd679-47e1-45ba-b7c4-911afed87fe4 -->","summary":"","htmlStringContent":"<!-- begin item 7a1fe9a2-fda0-4c1d-8103-face938b2812 --><!-- begin field c785cd5c-b301-43b0-8abc-bc587b9df07a --><ul><li><strong>The recommended dose of omeprazole oral suspension (2 mg/mL) is </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">BNF for Children, 2017</a>]<strong>:</strong><ul><li>1 month to 2 years — 700 micrograms/kg once daily. Increase if necessary to 3 mg/kg once daily (maximum of 20 mg).</li></ul></li><li><strong>Note that</strong> omeprazole suspension (unlicensed) is the only proton pump inhibitor liquid preparation available for administration to infants. This preparation is a 'special' and needs to be ordered by the pharmacy from a specials laboratory.</li></ul><!-- end field c785cd5c-b301-43b0-8abc-bc587b9df07a --><!-- end item 7a1fe9a2-fda0-4c1d-8103-face938b2812 -->","subChapters":[]},{"id":"d0a2a54b-bca6-553c-9594-d98e327eced6","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field fd1defc3-d4bb-47d5-b687-a9f200b7ecf3 --><h3>What are the contraindications and cautions?</h3><!-- end field fd1defc3-d4bb-47d5-b687-a9f200b7ecf3 -->","summary":"","htmlStringContent":"<!-- begin item dbacdd52-2fda-4c22-9f31-a9f200b7eccd --><!-- begin field 7494a4a7-568b-45a7-84ed-a9f200b7ecf3 --><ul><li>There are no known serious contraindications for omeprazole.</li><li>Omeprazole may increase the risk of gastro-intestinal infections (including <em>Clostridium difficile</em> infection). </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">BNF 76, 2018</a>] </p><!-- end field 7494a4a7-568b-45a7-84ed-a9f200b7ecf3 --><!-- end item dbacdd52-2fda-4c22-9f31-a9f200b7eccd -->","subChapters":[]},{"id":"81aad751-3971-5d5d-84e7-32d46c7c4e7c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1f9e5cd9-6b4b-4d9d-85e0-8e703256acd4 --><h3>What are the possible adverse effects?</h3><!-- end field 1f9e5cd9-6b4b-4d9d-85e0-8e703256acd4 -->","summary":"","htmlStringContent":"<!-- begin item 15e72441-d35e-480b-b52a-e383743c9283 --><!-- begin field 030e9987-1b2f-44bd-be81-6642e092fa34 --><ul><li><strong>Common or very common adverse effects of omeprazole include</strong> headache, diarrhoea, vomitting, nausea, abdominal pain, dry mouth, constipation, dizziness, insomnia, and skin rashes.</li><li><strong>Very infrequent cases of subacute cutaneous lupus erythematosus (SCLE)</strong> have been reported in people taking proton pump inhibitors (PPIs). Drug-induced SCLE can occur weeks, months, or years after exposure to the drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">MHRA, 2015</a>].<ul><li>If a child being treated with a PPI develops lesions, especially in sun-exposed areas of the skin, which are accompanied by arthralgia:<ul><li>Advise the parents and/or carers to avoid exposing the skin to sunlight.</li><li>Consider SCLE as a possible diagnosis.</li><li>Consider discontinuing PPI treatment unless it is imperative for a serious acid-related condition.</li></ul></li><li>Be aware that:<ul><li>A person who develops SCLE with a particular PPI may be at risk of the same reaction with another.</li><li>In most cases, symptoms resolve on PPI withdrawal. Topical or systemic steroids may be necessary for treatment of SCLE only if there are no signs of remission after a few weeks or months.</li></ul></li></ul></li><li><strong>Hypomagnesaemia</strong> may occur (more commonly after 1 year, but sometimes after 3 months) of treatment with omeprazole.</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gord-in-children/references/\">BNF for Children, 2017</a>]</p><!-- end field 030e9987-1b2f-44bd-be81-6642e092fa34 --><!-- end item 15e72441-d35e-480b-b52a-e383743c9283 -->","subChapters":[]},{"id":"ad4f40fe-cd19-5031-ac2d-c862e7880c60","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1d150103-6266-43d5-8b0a-864211f9741b --><h3>What are the possible drug interactions?</h3><!-- end field 1d150103-6266-43d5-8b0a-864211f9741b -->","summary":"","htmlStringContent":"<!-- begin item f8e85194-7a64-46ab-8d8b-9dfe203ef1e1 --><!-- begin field e0f085ce-9dec-4d4e-b16f-8c91e4b0ad21 --><ul><li><strong>Omeprazole is associated with a number of drug interactions, including:</strong><ul><li>Warfarin — International Normalized Ratio (INR) should be carefully monitored in people taking warfarin if omeprazole is started or stopped. Proton pump inhibitors can occasionally enhance the effects of warfarin.</li><li>Phenytoin — although this interaction is unlikely to be significant, the manufacturers recommend that people taking phenytoin are carefully monitored if omeprazole is started or stopped. Omeprazole can occasionally enhance the effects of phenytoin.</li></ul></li><li><strong>For a complete list of possible drug interactions of omeprazole, </strong>see the <a data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><!-- end field e0f085ce-9dec-4d4e-b16f-8c91e4b0ad21 --><!-- end item f8e85194-7a64-46ab-8d8b-9dfe203ef1e1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}